Worth reading
66In focus
Scored from 3 of 5 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
600000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)
Who receives how much
Number of shares delivered during the month: 600,000 shares (600,000 newly issued shares and 0 treasury shares transferred)
EVO FUND (the allottee at the time of issuance on 8 August 2025)
The lower thin line represents the existing number of shares to which these shares will be added.
発行済株式総数
Exercise ratio subject to exercise restrictions: 1.4% (600,000 shares delivered across all series / 44,613,940 listed shares as of the payment date for the issuance)
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥58–¥65 (the exercise price on each exercise date). Details of the adjustment clauses and the adjustment floor: not disclosed
Exercise period
Exercise of all remaining 19th Series Stock Acquisition Rights was suspended for the 68-trading-day period from 15 June 2026 (inclusive) through 18 September 2026 (inclusive).
Number of Stock Acquisition Rights
Total issued: 110,000 rights; unexercised as of the end of the month preceding the target month: 93,600 rights; unexercised as of the end of the target month: 87,600 rights; exercised during the target month: 6,000 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Announced on 23 July 2025: issuance through a third-party allotment of the 18th through 20th Series Stock Acquisition Rights (with exercise price adjustment clauses) and execution of warrant purchase agreements (commitment issue).
| Item | Details |
|---|---|
| Type of issuance or disposal | 19th Series Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses) |
| Number of shares to be issued or disposed of | Number of shares delivered during the month: 600,000 shares (600,000 newly issued shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (the allottee at the time of issuance on 8 August 2025) |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 1.4% (600,000 shares delivered across all series / 44,613,940 listed shares as of the payment date for the issuance) |
| Total number of issued shares | 55,972,640 shares (as of the end of the month preceding the target month) → Not disclosed |
| Exercise price | Exercise prices during the month: ¥58–¥65 (the exercise price on each exercise date). Details of the adjustment clauses and the adjustment floor: not disclosed |
| Exercise period | Exercise of all remaining 19th Series Stock Acquisition Rights was suspended for the 68-trading-day period from 15 June 2026 (inclusive) through 18 September 2026 (inclusive). |
| Number of Stock Acquisition Rights | Total issued: 110,000 rights; unexercised as of the end of the month preceding the target month: 93,600 rights; unexercised as of the end of the target month: 87,600 rights; exercised during the target month: 6,000 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | Announced on 23 July 2025: issuance through a third-party allotment of the 18th through 20th Series Stock Acquisition Rights (with exercise price adjustment clauses) and execution of warrant purchase agreements (commitment issue). |
Items this document does not state (18)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a report on the monthly exercise status, and the company has provided no explanation of the reasons for the exercises.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.